Nurix Therapeutics, Inc. $NRIX Stock Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA cut its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 51.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,130,453 shares of the company’s stock after selling 1,220,779 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Nurix Therapeutics were worth $26,798,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of Nurix Therapeutics in the 2nd quarter worth $212,769,000. Perceptive Advisors LLC lifted its holdings in shares of Nurix Therapeutics by 4.4% during the first quarter. Perceptive Advisors LLC now owns 3,710,877 shares of the company’s stock valued at $57,519,000 after purchasing an additional 155,000 shares in the last quarter. Trails Edge Capital Partners LP bought a new position in shares of Nurix Therapeutics during the second quarter valued at $38,166,318. Bank of America Corp DE purchased a new stake in shares of Nurix Therapeutics during the second quarter valued at $20,429,000. Finally, Dimensional Fund Advisors LP boosted its position in shares of Nurix Therapeutics by 81.1% during the first quarter. Dimensional Fund Advisors LP now owns 780,696 shares of the company’s stock valued at $12,094,000 after buying an additional 349,710 shares during the last quarter.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, Director Julia Gregory sold 22,583 shares of the stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $23.40, for a total value of $528,442.20. Following the transaction, the director owned 10,750 shares of the company’s stock, valued at approximately $251,550. This represents a 67.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Gwenn Hansen sold 3,957 shares of the firm’s stock in a transaction dated Friday, October 30th. The stock was sold at an average price of $26.28, for a total value of $103,989.96. Following the completion of the transaction, the insider directly owned 123,452 shares in the company, valued at $3,244,318.56. The trade was a 3.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 38,499 shares of company stock valued at $893,645. 6.70% of the stock is owned by company insiders.

Nurix Therapeutics Price Performance

NASDAQ NRIX opened at $16.33 on Thursday. The business’s fifty day moving average price is $23.67 and its 200-day moving average price is $20.17. The stock has a market capitalization of $1.78 billion, a price-to-earnings ratio of 7.07 and a beta of 1.80. Nurix Therapeutics, Inc. has a 1-year low of $12.01 and a 1-year high of $28.23.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Tuesday, October 13th. The company reported $4.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $5.33. Nurix Therapeutics had a return on equity of 49.34% and a net margin of 42.01%. The firm had revenue of $673.06 million for the quarter, compared to the consensus estimate of $24.35 million. Equities research analysts anticipate that Nurix Therapeutics, Inc. will post 1.14 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on NRIX. Oppenheimer boosted their target price on Nurix Therapeutics from $28.00 to $32.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 13th. Stifel Nicolaus set a $41.00 price target on shares of Nurix Therapeutics in a report on Tuesday, October 13th. Wall Street Zen upgraded shares of Nurix Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, October 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nurix Therapeutics in a research note on Thursday, October 15th. Finally, HC Wainwright boosted their price objective on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the company a “buy” rating in a report on Friday, October 16th. Fourteen analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $34.43.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, California. Founded in 2009, it develops medicines that aim to treat cancer and other diseases by changing the levels of specific proteins inside cells. The company’s technology focuses on protein degradation, using the cell’s natural protein-disposal system to remove disease-related proteins. Nurix also researches ways to regulate protein activity through ubiquitin signaling, a process that helps control how proteins function and are broken down.